Barrett Johnston, MD
Pain Medicine · Baton Rouge, LANPI 1962602250
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 805 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations.
Across 805 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Collegium Pharmaceutical, Inc.$1K
- Medtronic$1K
- Relievant Medsystems, Inc.$848
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$704
- AbbVie$671
- plus $7K from 51 others
What the payments were for
- Travel & lodging$4243%
- Food & beverage$13,91197%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$1,974
- SYNCHROMEDII$428
- Proclaim IPG$249
- HA MINUTEMAN G3-R$248
- mild Device Kit$163
- OMNICURVE$163
- SPINEJACK$163
- OPTABLATE$163
- Vanta$152
- Evoke$144
- Prospera$122
- Evoke SCS$119
- PROCLAIM$114
How this compares
$14,350 in reported general payments places this provider in the 85th percentile of 97 pain medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 795 | $64,712 |
| UbrelvyUbrogepant | 22 | $49,222 |
| Nurtec OdtRimegepant Sulfate | 24 | $25,071 |
| BelbucaBuprenorphine Hcl | 33 | $18,479 |
| OxycontinOxycodone Hcl | 12 | $17,080 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,214 | $15,713 |
| Diclofenac Sodium | 93 | $15,709 |
| MovantikNaloxegol Oxalate | 31 | $13,930 |
| LyricaPregabalin | 11 | $9,812 |
| Xtampza ErOxycodone Myristate | 13 | $9,133 |
| Gabapentin ErGabapentin | 14 | $8,474 |
| Gabapentin | 724 | $8,473 |
| Nucynta ErTapentadol Hcl | 12 | $7,851 |
| Lidocaine | 94 | $7,113 |
| Buprenorphine | 29 | $6,679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $671 | $49,22222 claims |
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er | $1,304 | $35,46358 claims |
| PfizerNurtec Odt, Lyrica | $251 | $34,88335 claims |
| Redhill Biopharma Inc.Movantik | $100 | $13,93031 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $264 | $5,84213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 97 pain medicine providers in Louisiana.
Other pain medicine in Baton Rouge
- Jason GremillionBaton Rouge$19K
- Samir PatelBaton Rouge$11K
- Samita DasBaton Rouge$10K
- Andrew BarkerBaton Rouge$9K
- Jake TrahanBaton Rouge$9K
- William GraugnardBaton Rouge$7K
- Paul KrammBaton Rouge$5K
- Jyoti PhamBaton Rouge$4K
- Thomas MyersMandeville$118K
- Alan KayeNew Orleans$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.